Exposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria-Reference-Cited by-同舟云学术

Exposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria

Published:2010-08 Issue:2 Volume:36 Page:137-144
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Sevillano D.,Aguilar L.,Alou L.,Giménez M.J.,González N.,Torrico M.,Cafini F.,Garcia-Rey C.,Garcia-Escribano N.,Prieto J.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference39 articles.

1. In vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae;Ku;J Microbiol Immunol Infect,2008

2. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom;Woodford;J Antimicrob Chemother,2008

3. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains;Jones;Clin Infect Dis,2006

4. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus;Tenover;Clin Infect Dis,2007

5. New antimicrobial agents as therapy for resistant Gram-positive cocci;Lentino;Eur J Clin Microbiol Infect Dis,2008

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella Pneumoniae isolates;Diagnostic Microbiology and Infectious Disease;2024-02

2. No dose adjustment of tigecycline is necessary during continuous renal replacement therapy: we are not sure;Critical Care;2020-02-20

3. Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains;Journal of Global Antimicrobial Resistance;2019-12

4. Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients;Current Infectious Disease Reports;2018-04-05

5. Appropriate Antimicrobial Therapy in Critically Ill Patients;Hot Topics in Acute Care Surgery and Trauma;2017-06-23